Immunotherapy as a treatment strategy in advanced stage and recurrent endometrial cancer: review of current phase III immunotherapy clinical trials

被引：8
|
作者：
Eskander, Ramez N. [1 ]
Powell, Matthew A. [2 ]
机构：
[1] Univ Calif San Diego, Dept Obstet Gynecol & Reprod Sci, Div Gynecol Oncol, Moores Canc Ctr, 3855 Hlth Sci Dr, La Jolla, CA 92093 USA
[2] Washington Univ, Sch Med, Dept Obstet & Gynecol, Div Gynecol Oncol, St Louis, MO 63110 USA
来源：
THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY | 2021年 / 13卷
关键词：
antiangiogenic therapy; chemotherapy; combination therapy; endometrial cancer; immune checkpoint inhibition; immunotherapy; tumor mutational burden; CARBOPLATIN; PACLITAXEL;
D O I：
10.1177/17588359211001199
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
The treatment of advanced stage, metastatic or recurrent endometrial cancer remains a clinically difficult scenario. Although combination carboplatin and paclitaxel is an effective standard-of-care regimen, alternate strategies have shown promise, particularly in biomarker select populations. In an effort to improve oncologic outcomes, investigators are exploring novel immunotherapy combinations. In this review, we discuss the clinical rationale and design of current phase III immuno-oncology clinical trials in patients with advanced stage or recurrent endometrial cancer.
引用
收藏
页数：9
相关论文
共 50 条
  • [1] The current status of immunotherapy in the treatment of primary advanced and recurrent endometrial cancer
    Fontenot, Virginia E.
    Tewari, Krishnansu
    CURRENT OPINION IN OBSTETRICS & GYNECOLOGY, 2023, 35 (01) : 34 - 42
  • [2] Clinical outcomes of advanced stage cancer patients treated with sequential immunotherapy in phase 1 clinical trials
    Dylan J. Martini
    Yuan Liu
    Julie M. Shabto
    Colleen Lewis
    Meredith R. Kline
    Hannah Collins
    Mehmet Akce
    Haydn T. Kissick
    Bradley C. Carthon
    Walid L. Shaib
    Olatunji B. Alese
    Rathi N. Pillai
    Conor E. Steuer
    Christina S. Wu
    David H. Lawson
    Ragini R. Kudchadkar
    Viraj A. Master
    Bassel F. El-Rayes
    Suresh S. Ramalingam
    Taofeek K. Owonikoko
    R. Donald Harvey
    Mehmet Asim Bilen
    Investigational New Drugs, 2019, 37 : 1198 - 1206
  • [3] Clinical outcomes of advanced stage cancer patients treated with sequential immunotherapy in phase 1 clinical trials
    Martini, Dylan J.
    Liu, Yuan
    Shabto, Julie M.
    Lewis, Colleen
    Kline, Meredith R.
    Collins, Hannah
    Akce, Mehmet
    Kissick, Haydn T.
    Carthon, Bradley C.
    Shaib, Walid L.
    Alese, Olatunji B.
    Pillai, Rathi N.
    Steuer, Conor E.
    Wu, Christina S.
    Lawson, David H.
    Kudchadkar, Ragini R.
    Master, Viraj A.
    El-Rayes, Bassel F.
    Ramalingam, Suresh S.
    Owonikoko, Taofeek K.
    Harvey, R. Donald
    Bilen, Mehmet Asim
    INVESTIGATIONAL NEW DRUGS, 2019, 37 (06) : 1198 - 1206
  • [4] CHARACTERISTICS AND CLINICAL OUTCOMES OF PATIENTS WITH RECURRENT MICROSATELLITE STABLE ENDOMETRIAL CANCER UNDERGOING EARLY PHASE IMMUNOTHERAPY CLINICAL TRIALS
    How, J.
    Jazaeri, A.
    Fu, S.
    Ahnert, J. Rodon
    Gong, J.
    Meric-Bernstam, F.
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2020, 30 : A112 - A112
  • [5] Clinical Outcomes of Patients with Recurrent Microsatellite-Stable Endometrial Cancer in Early-Phase Immunotherapy Clinical Trials
    How, Jeffrey A.
    Jazaeri, Amir A.
    Fu, Siqing
    Ahnert, Jordi Rodon
    Gong, Jing
    Stephen, Bettzy
    Dalla Pria, Hanna Ferreira
    Bhosale, Priya
    Johnson, Amber
    Yuan, Ying
    Meric-Bernstam, Funda
    Naing, Aung
    CANCERS, 2022, 14 (15)
  • [6] Clinical trials of immunotherapy for advanced prostate cancer
    Kuratsukuri, K
    Nishisaka, N
    Jones, RF
    Wang, CY
    Haas, GP
    UROLOGIC ONCOLOGY, 2000, 5 (06): : 265 - 273
  • [7] A comprehensive analysis of immunotherapy in advanced endometrial cancer (Review)
    Wang, Liping
    Liu, Lin
    Huo, Da
    Zhang, Yixiang
    ONCOLOGY LETTERS, 2024, 27 (02)
  • [8] Adiposity May Predict Survival in Patients With Advanced Stage Cancer Treated With Immunotherapy in Phase 1 Clinical Trials
    Martini, Dylan J.
    Kline, Meredith R.
    Liu, Yuan
    Shabto, Julie M.
    Williams, Milton A.
    Khan, Amir Ishaq
    Lewis, Colleen
    Collins, Hannah
    Akce, Mehmet
    Kissick, Haydn T.
    Carthon, Bradley C.
    Shaib, Walid L.
    Alese, Olatunji B.
    Pillai, Rathi N.
    Steuer, Conor E.
    Wu, Christina S.
    Lawson, David H.
    Kudchadkar, Ragini R.
    El-Rayes, Bassel F.
    Ramalingam, Suresh S.
    Owonikoko, Taofeek K.
    Harvey, R. Donald
    Master, Viraj A.
    Bilen, Mehmet Asim
    CANCER, 2020, 126 (03) : 575 - 582
  • [9] Impact of BMI on immunotherapy outcomes in patients with advanced or recurrent endometrial cancer
    Evans, Elizabeth
    Barton, Wade
    Harsono, Alfonsus Adrian
    Dholakia, Jhalak
    Arend, Rebecca
    GYNECOLOGIC ONCOLOGY, 2023, 176 : S193 - S194
  • [10] IMMUNOTHERAPY OF CANCER - SHORT REVIEW AND COMMENTARY ON CURRENT TRIALS
    MUGGIA, FM
    CANCER IMMUNOLOGY IMMUNOTHERAPY, 1977, 3 (01) : 5 - 9
12345